Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:12:26.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2025-05-22T03:51:02.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2025-05-07T20:18:23.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.8%
    Check dated 2025-04-30T18:45:16.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2025-04-23T15:52:00.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new study identifiers and collaborators, while removing detailed descriptions of a clinical trial involving nivolumab for acute myeloid leukemia. The revision number has also been updated.
    Difference
    41%
    Check dated 2025-04-16T13:15:49.000Z thumbnail image

Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.